Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018

Administered by Department of Health, Disability and Ageing

Legislation au F2018L00123 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

Issued by the Authority of the Minister for Health

 

Health Insurance Act 1973

Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018

Subsection 3C(1) of the Health Insurance Act 1973 (the Act) provides that the Minister may, by legislative instrument, determine that a health service not specified in an item in the pathology services table shall, in specified circumstances and for specified statutory provisions, be treated as if it were specified in the pathology services table. 

 

The pathology services table is set out in the regulations made under subsection 4A(1) of the Act, which is re-made each year. The most recent version of the regulations is the Health Insurance (Pathology Services Table) Regulations 2017 which commenced on 17 June 2017.

Purpose

The purpose of the Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018 is to amend the Health Insurance (ALK Gene Testing) Determination 2017. The Determination will amend the descriptor of item 73341 to reflect the listing on the Pharmaceutical Benefits Scheme (PBS) of alectinib to treat locally advanced or metastatic non-small cell lung cancer (NSCLC).

 

Item 73341 funds a fluorescence in situ hybridisation (FISH) test for patients with NSCLC. Specifically, the test is for the anaplastic lymphoma kinase (ALK) gene rearrangement, to determine eligibility for treatment with crizotinib or ceritinib on the PBS. The Determination will amend item 73341 to allow for ALK gene testing to determine eligibility for treatment with alectinib, in addition to crizotinib or ceritinib, on the PBS. This change was recommended by Pharmaceutical Benefits Advisory Committee (PBAC) at its meeting in July 2017, and endorsed by the Medical Services Advisory Committee (MSAC).

Consultation

Consultation was previously undertaken for the original listing of item 73341 in the Health Insurance (ALK Gene Testing) Determination 2015.  The creation of the new item was considered and agreed to by MSAC and informed by clinical experts from the Pathology Clinical Committee. There is no change to the pathology service which is listed in the 2015 Determination.

 

MSAC reviews new or existing medical services or technology, and the circumstances under which public funding should be supported through listing on the MBS.  This includes the listing of new items, or amendments to existing items on the MBS. 

 

The listing of alectinib was recommended by PBAC, and endorsed by MSAC.

 

Details of the Determination are set out in the Attachment.

The Determination commences the day after registration.

The Determination is a legislative instrument for the purposes of the
Legislation Act 2003.

          

Authority:     Subsection 3C(1) of the

 Health Insurance Act 1973

 

ATTACHMENT

 

Details of the Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018

 

Section 1 – Name of Determination

 

Section 1 provides for the Determination to be referred to as the Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018.

 

Section 2 – Commencement

 

Section 2 provides that the Determination commences on the day after registration.

Section 3 – Authority

 

Section 3 provides that the Determination is made under subsection 3C(1) of the Health Insurance Act 1973.

 

Section 4 – Amendment of the Health Insurance (ALK Gene Testing) Determination 2017

This section provides that Schedule 1 amends the Health Insurance (ALK Gene Testing) Determination 2017.

Schedule 1 – Amendments

Schedule 1 amends the descriptor of item 73341 to omit “crizotinib or ceritinib” and substitute with “crizotinib, ceritinib or alectinib”.

Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

 

Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018
 

This Determination is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Disallowable Legislative Instrument

The Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018 (the Determination) amends the Health Insurance (ALK Gene Testing) Determination 2017 to allow ALK gene testing item 73341 to determine eligibility for treatment with alectinib on the Pharmaceutical Benefits Scheme.

Human rights implications

The Determination engages Articles 9 and 12 of the International Covenant on Economic Social and Cultural Rights (ICESCR), specifically the rights to health and social security.

The Right to Health

The right to the enjoyment of the highest attainable standard of physical and mental health is contained in Article 12(1) of the ICESCR. The UN Committee on Economic Social and Cultural Rights (the Committee) has stated that the right to health is not a right for each individual to be healthy, but is a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.

The Committee reports that the ‘highest attainable standard of health’ takes into account the country’s available resources. This right may be understood as a right of access to a variety of public health and health care facilities, goods, services, programs, and conditions necessary for the realisation of the highest attainable standard of health.

The Right to Social Security

The right to social security is contained in Article 9 of the ICESCR. It requires that a country must, within its maximum available resources, ensure access to a social security scheme that provides a minimum essential level of benefits to all individuals and families that will enable them to acquire at least essential health care. Countries are obliged to demonstrate that every effort has been made to use all resources that are at their disposal in an effort to satisfy, as a matter of priority, this minimum obligation.

The Committee reports that there is a strong presumption that retrogressive measures taken in relation to the right to social security are prohibited under ICESCR. In this context, a retrogressive measure would be one taken without adequate justification that had the effect of reducing existing levels of social security benefits, or of denying benefits to persons or groups previously entitled to them. However, it is legitimate for a Government to re-direct its limited resources in ways that it considers to be more effective at meeting the general health needs of all society, particularly the needs of the more disadvantaged members of society.


Analysis

This Determination will maintain rights to health and social security by ensuring access to publicly subsidised health services which are clinically effective and cost-effective.

Conclusion

This Disallowable Legislative Instrument is compatible with human rights as it has a positive effect on human rights issues.

Celia Street

Assistant Secretary

Diagnostic Imaging and Pathology Branch

Medical Benefits Division

Department of Health

 

Overview

The Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018, enacted under subsection 3C(1) of the Health Insurance Act 1973, aims to update the descriptor of item 73341 in the Health Insurance (ALK Gene Testing) Determination 2017. This amendment was made to reflect the listing of alectinib on the Pharmaceutical Benefits Scheme (PBS) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). The amendment allows for ALK gene testing to determine eligibility for treatment with alectinib, in addition to crizotinib or ceritinib, on the PBS. This change was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) and endorsed by the Medical Services Advisory Committee (MSAC). The Determination ensures that patients with NSCLC have access to effective treatment options by expanding the scope of pathology services covered under the Health Insurance Act. The Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018 was issued by the Minister for Health and is compatible with human rights as it upholds the rights to health and social security by ensuring access to publicly subsidised health services. This amendment aligns with the principles of the International Covenant on Economic, Social and Cultural Rights, specifically Articles 9 and 12, which address the rights to social security and the highest attainable standard of physical and mental health. By amending the descriptor of item 73341, the Determination facilitates access to clinically effective and cost-effective health services, thereby maintaining the rights to health and social security for individuals requiring ALK gene testing.

Scope and Application

The Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018 applies to persons who are eligible for health insurance benefits under the Health Insurance Act 1973 and who require ALK gene testing to determine their eligibility for treatment with alectinib, crizotinib, or ceritinib on the Pharmaceutical Benefits Scheme. This determination applies nationally as it is a legislative instrument made under the authority of the Commonwealth of Australia. The amendment specifically relates to the descriptor of item 73341 in the pathology services table, which funds a fluorescence in situ hybridisation test for patients with non-small cell lung cancer. The amendment excludes any other pathology services not specified in the determination. The application of the Determination can be extended or restricted through subordinate instruments made under the Health Insurance Act 1973. This Determination ensures that eligible individuals have access to publicly subsidised health services that are both clinically effective and cost-effective.

Key Provisions

The Health Insurance (Section 3C Pathology Services—ALK Gene Testing) Amendment Determination 2018 amends the Health Insurance (ALK Gene Testing) Determination 2017, primarily by altering the descriptor of item 73341 (Section 4). This item pertains to the fluorescence in situ hybridisation (FISH) test for the anaplastic lymphoma kinase (ALK) gene rearrangement in patients with non-small cell lung cancer (NSCLC). The amendment allows this test to determine eligibility for treatment with alectinib, in addition to crizotinib or ceritinib, under the Pharmaceutical Benefits Scheme (PBS) (Schedule 1). The Determination is made under subsection 3C(1) of the Health Insurance Act 1973 and commences on the day after its registration (Section 2 and Section 3). Under this Determination, the parties or entities governed must adhere to the updated descriptor of item 73341, which now includes alectinib as a treatment option for patients with NSCLC who test positive for the ALK gene rearrangement. This amendment ensures that patients who are eligible for alectinib will have their treatment costs subsidised by the PBS, provided they meet the clinical criteria set out in the Determination. The updated descriptor clarifies the scope of the pathology service covered under the Health Insurance Act 1973, ensuring that the test is available for the correct patient population. There are no explicit offences, penalties, or civil/criminal consequences outlined in the Determination for breach of its provisions. However, the Determination operates within the broader framework of the Health Insurance Act 1973, which includes provisions for penalties and enforcement actions for non-compliance with the Act. These could include fines or other sanctions for providers who do not adhere to the requirements set out in the Determination or the broader legislative framework. The specific penalties would be determined in accordance with the relevant provisions of the Health Insurance Act 1973 and any applicable regulations.

Legal classification tags

Area of Law
Health Law
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.